Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. NKE
3. PANW
4. CL
5. SNDK
6. TAP
7. DELL
8. ROIV
9. ANET
10. BE

Go back to Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
(NASDAQ: TENX) Delayed: 1.94 +0.16 (8.99%)
Previous Close $1.78    52 Week High $3.40 
Open $1.82    52 Week Low $1.34 
Day High $1.96    P/E N/A 
Day Low $1.80    EPS $0.00 
Volume 4,542,531